Where is Seneca Biopharma's stock traded?

Seneca Biopharma's shares are traded on the NASDAQ under the symbol SNCA.

When did the company go public?

Seneca Biopharma went public in December 2006.

Where are Seneca Biopharma's headquarters located?

Seneca Bio
20271 Goldenrod Lane, Suite 2024
Germantown, MD 20876
Phone: 301.366.4960

When do Seneca Biopharma's fiscal quarters end?

First Quarter: March 31
Second Quarter: June 30
Third Quarter: September 30
Fourth Quarter: December 31

Who is Seneca Biopharma's independent auditor?

Dixon Hughes Goodman LLP
809 Glen Eagles Court
Suite 200
Baltimore, MD 21286
T: 410-838-8000
F: 410-296-4815

How can I buy Seneca Biopharma stock?

You may purchase CUR stock through a registered stockbroker.

Does Seneca Biopharma have a direct stock purchase plan?

No. Shares can be purchased through a registered or discount stock brokerage firm.

Whom should I contact with questions about my stock ownership?

Beneficial shareholders with shares held by a broker in the name of the brokerage house should contact their broker on all administrative matters. If you are a registered shareholder and have questions regarding your account status (e.g. number of shares, missing certificates, address changes, etc.), please contact Seneca Biopharma's transfer agent.

Who is Seneca Biopharma's transfer agent?

American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
T: 718-921-8200

Where can I find financial information about Seneca Biopharma?

Seneca Biopharma files periodic reports, including Annual Reports (Form 10-K), Quarterly Reports (Form 10-Q) and Current Reports (Form 8-K) with the Securities and Exchange Commission (SEC). These reports are available on our SEC Filings page. In addition, Seneca Biopharma posts recent financial information in the form of quarterly earnings press releases on the Press Releases page.

Whom should I contact if I have more questions about investing in Seneca Biopharma?


Who is Seneca Biopharma's PR contact?


What is Seneca Biopharma’s expanded access policy?

At Seneca Biopharma, we are committed to providing novel treatment options to patients living with serious nervous system diseases and conditions.  To do this, Seneca Biopharma conducts clinical trials to assess the safety and efficacy of our investigational therapies, which may allow us to obtain the necessary regulatory approvals and eventually provide patients with broad access to these therapies. 

Currently, Seneca Biopharma does not make its unapproved therapeutic agents available on an expanded access or compassionate use basis.  We feel that providing access to our investigational therapies outside of our ongoing and critical clinical trials may delay or jeopardize the approval of therapies, by reducing the supply of study agents or adversely affecting the data collection process. By focusing on clinical development and seeking regulatory approval, it is our goal to offer our therapies to the largest number of patients as quickly as possible.

If you have any questions about our expanded use policy, please contact us at Danielle Spangler at dspangler@senecabio.com

For more information regarding our clinical trials, visit clinicaltrials.gov

Seneca Biopharma may revise this expanded access policy at any time.  Additionally, the posting of this policy by Seneca Biopharma shall not serve as a guarantee of access to any specific investigational therapy by any individual patient.